Inactive

AMENDMENT 3 IS ISSUED TO EXTEND THE DUE DATE FOR SUBMISSION OF QUOTES TO MARCH 14, 2024, 12PM ET. Amendment 3 is provided in the ATTACHMENTS section of this posting. Quoters are required to acnowledge... AMENDMENT 3 IS ISSUED TO EXTEND THE DUE DATE FOR SUBMISSION OF QUOTES TO MARCH 14, 2024, 12PM ET. Amendment 3 is provided in the ATTACHMENTS section of this posting. Quoters are required to acnowledge each Solicitation Amendment by including each Standard Form (SF-30) signed by your organizations signature authority and completing Block 8 with your Organization Name and Address, and submitting it along with your quote submission. *************************************************************************************** AMENDMENT 2 was ISSUED TO EXTEND THE DUE DATE FOR SUBMISSION OF QUOTES. Amendment 2 is provided in the ATTACHMENTS section of this posting. Quoters are required to acnowledge each Solicitation Amendment by including each Standard Form (SF-30) signed by your organizations signature authority and completing Block 8 with your Organization Name and Address, and submitting it along with your quote submission. *************************************************************************************** 2/20/2024: Reuploaded the file "RFQ75N91023Q00142 w attachments_FINAL 2 Feb 2024" since prior uploaded version appeared to have been corrupted and couldn't be accessed. It is a duplicate file and no changes were made. Amendment 1 of the Solication attached. Amendment 1 extended the Due Date for Submission of Quotes. It also provided Answers to Solicitations Questions. Quoters are required to acnowledge each Solicitation Amendment by including each Standard Form (SF-30) signed by your organizations signature authority and completing Block 8 with your Organization Name and Address, and submitting it along with your quote submission. **************************************************************************************** The purpose of this acquisition is to collect data for the National Cancer Institute (NCI) Patterns of Care (POC) FY2024 Study. The NCI Pattern of Care studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. This solicitation for the FY 2024 NCI Patterns of Care Study is investigating patterns of care for patients with prostate and ovarian cancers for Diagnosis Year 2021. The study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic in the medical record. The primary objectives of this POC Study are to: 1) describe the use of recommended biomarker tests which shall be verified with the treating physician/physician office staff or with a unified medical record (record with all inpatient and outpatient records in a single file) or complete medical records (all inpatient and outpatient cancer treatment records obtained from more than one hospital/healthcare system/medical practice); 2) describe the use of targeted therapy which shall be verified with the treating physician/physician office staff or with a unified or complete medical record. 3) describe the use of adjuvant therapy, which shall be verified with the treating physician/physician office staff or with a unified or complete medical records; 4) characterize the practice patterns in different communities; 5) compare the patterns of treatment (surgery, radiation therapy, systemic therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, and other adjuvant therapy) over time and by age, sex, race/ethnicity, and insurance status; 6) describe comorbidities and the effect of co-morbid conditions on treatment; 7) describe treatment by hospital characteristics (i.e., for profit vs. not for profit, teaching vs. non-teaching, bed size, etc.); 8) describe the use of diagnostic tests and compare their use by demographic variables; 9) abstract information documented in the medical record on delays or changes in diagnosis, treatment, and supportive/palliative care among individuals diagnosed with cancer specifically due to the COVID-19 pandemic; 10) assess the incidence of cancer recurrence and metastasis following initial diagnosis; and 11) describe medical record documentation of patient financial impacts due to the COVID-19 pandemic potentially affecting cancer care. SEE ATTACHED REQUEST FOR QUOTE that contains all the relevant attachments. Word/editable versions of some of those attachments have also been attached separately for ease of quote preparation purposes (but are exact duplicates of what is already in the full "RFQ 75N91023Q00142 w Attachments" file.)